HeartSciences Files Definitive Proxy for Fortitude Merger, But Delay Raises Questions

What happened

HeartSciences Inc. filed its definitive proxy statement on October 21, 2026, for the proposed business combination with Fortitude Mining, with the board unanimously recommending shareholders vote in favor. This filing arrives later than the 90-day checkpoint of September 27, 2026, outlined in the prior master report, indicating timeline slippage, but remains ahead of the October 31, 2026 waiver deadline on the Streeterville note redemption rights. The delay likely reflects extended SEC review or preparation challenges, and the proxy now sets the stage for a shareholder meeting to approve the merger, Nasdaq Rule 5635 issuance, and related proposals. While the filing is a necessary milestone, closing still requires shareholder approval and other conditions, and the tight window before the waiver expiry increases the risk of a liquidity crunch if the vote is delayed. The proxy will also reveal governance terms, including management incentives tied to closing, which may attract scrutiny from legacy shareholders facing extreme dilution to roughly 5% post-close ownership.

Implication

Investors should focus on the special meeting date and whether the transaction can close before October 31, 2026, when the noteholder waiver expires. The delayed proxy filing suggests the timeline is tight, and any further slippage could trigger dilutive redemptions. Vote dynamics are critical: board recommends FOR and support agreements exist, but the extreme dilution to legacy holders and merger-linked bonuses may attract opposition. If the deal closes, attention shifts to Fortitude's mining execution and Zcash economics. Until then, HSCS remains a high-risk transaction vehicle with limited standalone value.

Thesis delta

The core thesis that HSCS serves as a reverse-merger vehicle for Fortitude remains intact, but the timing has deteriorated relative to the 90-day checkpoint. The proxy filing is a positive step but was expected earlier; the delay increases the probability that closing extends beyond the waiver deadline. As such, the balance of risk has shifted slightly more negative, though the deal is still viable if approvals move swiftly.